ArticleBJC reports2025

HER2 amplification and HER2 low expression in endometrial carcinoma: prevalence across molecular, histological and clinicopathological risk groups.

Karoliina Aro et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.